An observational study in Bicuspid Aortic Valve (BAV), Aortic Aneurysm and TAVR, sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine. Completed at 2 sites in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-08-24.
Sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Bicuspid aortic valve (BAV) is the most common congenital valvular malformation, characterized by heterogeneous phenotypic subtypes that predispose patients to secondary aortic pathologies, including valvular dysfunction and ascending aortic dilation. With approximately 50% of BAV patients developing aortic dilation, a prevalence that continues to rise, accurate assessment of postoperative aortic remodeling remains a critical unmet clinical need for early risk stratification and optimized therapeutic decision-making. Currently, clinical surveillance relies heavily on periodic manual measurement of the maximum aortic diameter on follow-up computed tomography angiography (CTA), yet this approach suffers from several inherent limitations. It is a lagging indicator that detects irreversible wall damage only after significant enlargement has occurred. It oversimplifies complex three-dimensional morphological changes into a single linear dimension. It exhibits substantial intra- and inter-observer variability. It is also inefficient for large-scale longitudinal data management. Although alternative metrics such as computational fluid dynamics (CFD) derived hemodynamic parameters and morphological geometric features have been explored, existing methods remain constrained by static single-time-point analyses that fail to capture the dynamic biomechanical evolution driving aneurysm progression, high technical barriers that preclude routine clinical integration, and a lack of comprehensive models that systematically integrate dynamic deformation, static anatomy, and hemodynamic information. To address these gaps, this study aims to develop a fully automated, quantitative, and dynamic risk prediction system that leverages vascular deformation mapping (VDM) for noninvasive early detection of regional aortic deformation, integrates multiparameter features including dynamic deformational, static anatomical, and hemodynamic characteristics through an artificial intelligence model, and delivers intuitive structured reports to directly support clinical decision-making, thereby enabling earlier intervention and improved patient outcomes.
This retrospective multi-center study aims to develop an automated AI system integrating Vascular Deformation Mapping (VDM) and Computational Fluid Dynamics (CFD) to predict aortic dilation risk in BAV patients after TAVR. Approximately 1,000 patients with pre-operative, post-operative, and follow-up CTA will be enrolled from two Chinese hospitals. The system automatically segments the aorta using 3D U-Net++, quantifies local deformation via deformable registration, and extracts dynamic, anatomical, and hemodynamic features. An XGBoost model trained on historical data (n=200) with 1-year outcomes outputs risk probability and category. The primary outcome is a validated prediction model; secondary outcomes include deformation pattern quantification and automated report generation. All data are anonymized. The target sample size is 1,000 patients.
62 studies on the registry are indexed under Bicuspid Aortic Valve Disease; 21 are open to participants now.
This study's enrollment of 1,000 is above the median of 236 across 38 observational studies indexed under Bicuspid Aortic Valve Disease.
Browse Bicuspid Aortic Valve Disease studies →Second Affiliated Hospital, Zhejiang University, School of Medicine is the lead sponsor of 100 studies on the registry; 68 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Approximately 1,000 BAV patients who underwent TAVR will be retrospectively enrolled from two Chinese tertiary hospitals. Eligible patients are aged 18-85 years with serial CTA (pre-op, post-op, follow-up) covering the aorta from supra-aortic branches to iliac arteries. Exclusions: connective tissue disorders, prior aortic surgery, dissection, isolated aneurysm, poor image quality, or registration failure. No additional interventions are administered. All patients are analyzed as a single observational cohort.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients are eligible for inclusion if they are male or non-pregnant female aged 18 to 85 years, diagnosed with Bicuspid Aortic Valve (BAV) by CTA, and have successfully undergone Transcatheter Aortic Valve Replacement (TAVR) with available pre-operative, post-operative (1-3 months), and follow-up (6-12 months) CTA imaging. The CTA scan range must cover cranially at least the origin of the brachiocephalic trunk, left common carotid artery, and left subclavian artery, and caudally at least the origin of the internal and external iliac arteries.
Exclusion Criteria:
Patients are excluded if they have traumatic or iatrogenic aortic dissection, isolated aortic aneurysm without BAV, connective tissue disorders such as Marfan syndrome or Ehlers-Danlos syndrome, or prior cardiac or aortic surgery including surgical aortic valve replacement or aortic repair. Additional exclusions include insufficient number of CTA scans or inadequate scan range, poor CTA image quality due to motion artifacts or inadequate contrast enhancement precluding accurate segmentation, or image registration failure precluding completion of VDM analysis.
Bicuspid Aortic Valve (BAV) patients aged 18-85 years who have successfully undergone Transcatheter Aortic Valve Replacement (TAVR) and have available pre-operative, post-operative, and follow-up CTA imaging with scan coverage from supra-aortic branches to iliac arteries. Patients with connective tissue disorders (e.g., Marfan syndrome), prior cardiac/aortic surgery, traumatic or iatrogenic dissection, or insufficient imaging quality will be excluded. All enrolled patients will be retrospectively analyzed as a single observational cohort to develop and validate an AI-based risk prediction model for aortic dilation. No intervention or randomization is applied.
Procedure: Transcatheter Aortic Valve Replacement
Transcatheter Aortic Valve Replacement (TAVR) is a minimally invasive procedure in which a collapsible replacement valve is inserted via catheter through the femoral artery or other access routes and deployed within the native diseased aortic valve. In this study, TAVR was performed as standard clinical care in BAV patients with severe aortic stenosis or regurgitation. Post-procedural CTA imaging was obtained as part of routine follow-up to monitor aortic remodeling and detect potential dilation. The present study retrospectively analyzes the serial CTA images acquired before and after this procedure; no additional intervention is administered for research purposes.
Development and Validation of a Multi-dimensional Risk Prediction Model for Aortic Dilation
The model is developed using machine learning (XGBoost) integrating dynamic deformation features (e.g., radial displacement percentiles from VDM), static anatomical features (e.g., aneurysm volume), and optional hemodynamic features (e.g., wall shear stress from CFD). Model performance (discrimination and calibration) will be assessed using the Area Under the Receiver Operating Characteristic Curve (AUC) and calibration plots. The outcome is the model's predictive accuracy for aortic dilation status.
Time frame: Post-TAVR 1-year follow-up
Quantification of Aortic Deformation via Vascular Deformation Mapping (VDM)
Aortic deformation is quantified by calculating the 3D displacement field between pre- and post-TAVR CTA images using a highly regularized deformable registration algorithm. The primary metric is the 90th percentile of radial displacement (mm) of the aortic surface. Higher values indicate greater local expansion.
Time frame: Post-TAVR 3-month follow-up
Change in Aortic Dimensions Measured by Automated 3D Analysis
Change in maximum aortic diameter, cross-sectional area, and volume, automatically measured from 3D aortic models segmented by a deep learning algorithm. This provides a comprehensive assessment of morphological change beyond the traditional single-diameter measurement.
Time frame: Post-TAVR 1-year follow-up (relative to pre-TAVR baseline)
Clinical Utility Assessment of the Automated Reporting System
The clinical utility of the automated system is evaluated by the proportion of successfully generated, structured clinical reports that are interpretable without manual correction. This outcome measures the feasibility of integrating this advanced AI-driven analysis into routine clinical workflow.
Time frame: Upon study completion, up to 36 months
Plan to share: No
No publications or documents are linked to this record.
Ran from Jan 2020 to primary completion in Dec 2025, 71 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bicuspid Aortic Valve Disease →
Second Affiliated Hospital, Zhejiang University, School of Medicine →